UNSPSC 51381702: Benorilate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H15NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W1QX9DV96G, chemically known as salicylic acid, acetate, ester with 4-hydroxyacetanilide but generally known as benorilate, which bears US NIH Compound Identifier 21102. European Medicines Agency schedules Benorilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05722MIG.

UNSPSC 51381702 Benorilate is a Commodity code that classifies pharmaceutical products, but the recent state and local procurement activity tagged under it does not reflect benorilate specifically—instead, the code captures a broader range of pharmaceutical procurement including naloxone, generic multi-source pharmaceuticals, and over-the-counter products being solicited by health departments, state agencies, and cooperative purchasing alliances. State and local governments use this code tier to source finished pharmaceuticals for community health programs, pharmacy benefit initiatives, and institutional distribution networks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The procurement process spans competitive IFBs for specific pharmaceutical quantities and RFPs establishing framework agreements with multiple vendors and authorized wholesalers serving a consortium of state and local members.

Recent opportunities show activity in Florida, Texas, and Minnesota-led cooperative purchasing. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline and quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs as a preliminary market intelligence step before formal solicitation. MMCAP, administered by the Minnesota Department of Administration and serving multiple states including Oregon, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and awarded contracts effective July 1, 2026; the RFP requires vendors to work through three authorized wholesalers and emphasizes price competitiveness (weighted at 75 percent of evaluation), cGMP and DSCSA compliance, and $5,000,000 commercial general liability coverage.